- Home
- REVB vs ATNF Comparison
REVB vs ATNF Comparison
Compare REVB & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- ATNF
- Stock Information
- Founded
- REVB 2020
- ATNF 2016
- Country
- REVB United States
- ATNF United States
- Employees
- REVB N/A
- ATNF N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- ATNF Health Care
- Exchange
- REVB Nasdaq
- ATNF Nasdaq
- Market Cap
- REVB 3.7M
- ATNF 3.8M
- IPO Year
- REVB N/A
- ATNF N/A
- Fundamental
- Price
- REVB $0.79
- ATNF $0.83
- Analyst Decision
- REVB
- ATNF
- Analyst Count
- REVB 0
- ATNF 0
- Target Price
- REVB N/A
- ATNF N/A
- AVG Volume (30 Days)
- REVB 3.0M
- ATNF 35.4K
- Earning Date
- REVB 08-08-2025
- ATNF 08-11-2025
- Dividend Yield
- REVB N/A
- ATNF N/A
- EPS Growth
- REVB N/A
- ATNF N/A
- EPS
- REVB N/A
- ATNF N/A
- Revenue
- REVB N/A
- ATNF N/A
- Revenue This Year
- REVB N/A
- ATNF N/A
- Revenue Next Year
- REVB N/A
- ATNF N/A
- P/E Ratio
- REVB N/A
- ATNF N/A
- Revenue Growth
- REVB N/A
- ATNF N/A
- 52 Week Low
- REVB $0.74
- ATNF $0.66
- 52 Week High
- REVB $56.00
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- REVB 26.64
- ATNF 35.60
- Support Level
- REVB $0.74
- ATNF $0.95
- Resistance Level
- REVB $0.88
- ATNF $1.04
- Average True Range (ATR)
- REVB 0.06
- ATNF 0.08
- MACD
- REVB 0.08
- ATNF -0.01
- Stochastic Oscillator
- REVB 32.49
- ATNF 17.41
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.